Bayer CEO warns of tough 2025 as turnaround plan beds in - NEWS 05.03.25
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
Today, we learn that Lawrence Tallon has been named head of the MHRA, effective as of 1st April. He will replace Dame June Raine, who is retiring.
Elsewhere, the FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, and the FDA has also begun a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth.
And Jazz Pharmaceuticals has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August, but for Bayer things will get tougher in 2025 before they get better, according to the group’s CEO Bill Anderson, as its 2024 financial results are released.
For those in search of a longer read today, find out which appointments were made in the first month of this year with a new edition of Changing Faces, and discover more about Viseven’s eWizard tool, and how it can assist localisation efforts, in a new Solution Spotlight.
All this and more on pharmaphorum.com.?
News
Lawrence Tallon has been named head of the MHRA, effective 1st April, replacing Dame June Raine who is retiring.
The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.
FDA starts a review of Roche's Gazyva as a treatment for lupus nephritis, an indication that analysts think could unlock renewed sales growth.
Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.
Things will get tougher before they get better at Bayer, according to CEO Bill Anderson, as the group reports its 2024 financial results.
Views & Analysis
With the right process and tools, localisation can become a well-oiled machine. Viseven’s approach involving eWizard has been tried and tested by multiple life sciences businesses, proving its efficiency.
Welcome to the first edition of Changing Faces for 2025. January kicked off the year with a flurry of notable leadership transitions across the pharmaceutical and biotechnology sectors. Here is a detailed look at the latest hires and departures.
The social media landscape is shifting. As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin is rapidly gaining traction.
The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the pharmaceutical sector.
In recognition of Rare Disease Day, Dr Kamran Iqbal, head of medical affairs and patient advocacy in global rare diseases at Chiesi UK, discussed with pharmaphorum the company’s evolving role in rare diseases.
Podcasts & Videos
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jason Bock, co-founder and CEO of CTMC, a first-of-its-kind cell therapy engine.
Prior authorisations (or PAs) have long put a burden on pharmacy and medical practices, ultimately causing delays for patients. In a new podcast, web editor Nicole Raleigh speaks with Andrew Burns, chief revenue officer at DrFirst, about the ramifications of delayed patient care when it comes to specialty medications.
pharmaphorum editor-in-chief Jonah Comstock met with Albert Seymour, CEO of Seamless Therapeutics, a genetics medicines company leveraging new technology that allows them to edit the genes in a wide range of cells with the enzyme recombinase.
CEO Ryan Spencer of Dynavax Technologies joins Jonah Comstock in a video interview discussing JP Morgan Week 2025.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Children’s National Medical Center.
Webinars & White Papers
In this webinar, sponsored by IPG Health, discover how industry insiders are unlocking the potential of CGTs in rare disease care, the unique hurdles facing pharma and patients, and the transformative opportunities these therapies bring.
In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication planners and medical affairs communications teams can leverage the new impact metrics that matter for journal selection.
In a recent webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’, this forward-looking session explored how imagination and innovation are reshaping the future of healthcare. Available now on demand.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
Partner Content and Events
Transforming Cell- & Biologic-based TCR Approaches
Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, With Optimized Efficacy, Potency, Mechanisms & Differentiated IP
The 3rd Obesity & Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling the obesity epidemic.
With more cytokine-based drugs entering clinical trials and novel combination and masking technologies being used, there is a growing need for experts to discuss, understand, and build on the current potential of cytokine-based drugs.
7th Neuroimmunology Drug Development Summit | February 25-27 2025 | Boston, MA The 7th Neuroimmunology Drug Development Summit is biopharma’s must attend forum to learn, benchmark and debate.